TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8346000

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3579012

Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone exposure
Number of subjects: 8
Study: 28942683

Group type: EXPERIMENTAL
Intervention: Volar locking plate fixation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Compression screw fixation
Number of subjects: 16
Study: 29550238

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) with 'rescue' CPAP backup
Number of subjects: 435

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) without 'rescue' CPAP backup
Number of subjects: 435

Group type: COMPARATOR
Intervention: High-flow therapy with 'rescue' CPAP backup
Number of subjects: 435

Group type: COMPARATOR
Intervention: High-flow therapy without 'rescue' CPAP backup
Number of subjects: 435
Study: 27425415

Group type: EXPERIMENTAL
Intervention: Active SPG acupuncture (AA group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham SPG acupuncture (SA group)
Number of subjects: 39
Study: 24004556

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exercise combined with Mediterranean Diet (MD)
Number of subjects: 15
Study: 23662515

Group type: EXPERIMENTAL
Intervention: Unbalanced solutions in infusion therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Balanced solutions in infusion therapy
Number of subjects: 54
Study: 20230331

Group type: EXPERIMENTAL
Intervention: Folic acid 5mg tablets daily for 4 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 46
Study: 17652268

Group type: EXPERIMENTAL
Intervention: Interactive educational intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Baseline barrier assessment using qualitative and quantitative techniques
Number of subjects: 24
Study: 16133949

Group type: EXPERIMENTAL
Intervention: Juror orientation videotape
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not exposed to the orientation videotape (Control)
Number of subjects: 0
Study: 12138953

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) for 14 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (placebo) for 14 weeks
Number of subjects: 29
Study: 10444703

Group type: EXPERIMENTAL
Intervention: Unilateral ischemic lesions of the frontal eye field
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Unilateral ischemic lesions of the dorsolateral prefrontal cortex
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combined lesions of the frontal eye field and dorsolateral prefrontal cortex
Number of subjects: 6
Study: 8679292

Group type: EXPERIMENTAL
Intervention: rgp160 in alum at 0, 1, and 6 months (group A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: rgp160 at 0 and 1 months followed by V3 at 3 and 6 months formulated in alum (group B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: rgp160 at 0 and 1 months followed by V3 at 3 and 6 months formulated in Freund's incomplete adjuvant (FIA) (group C)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: rgp160
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: V3 peptide
Number of subjects: 25
Study: 2143104

Group type: EXPERIMENTAL
Intervention: Trospectomycin (75 to 1,000 mg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trospectomycin (600 mg and above)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trospectomycin (1,000 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 841605

Group type: EXPERIMENTAL
Intervention: Irradiation under 95% O2 plus 5% CO2 inhalation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uneven fractionation irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study: 30958319

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation over the contralesional cerebellar hemisphere + cathodal transcutaneous spinal direct current stimulation in combination with robotic training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation over the ipsilesional cerebellar hemisphere + cathodal transcutaneous spinal direct current stimulation in combination with robotic training
Number of subjects: 40
Study: 27878566

Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart (faster aspart)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 46
Study: 25877495

Group type: EXPERIMENTAL
Intervention: B vitamin supplementation (folic acid 0.8 mg, vitamin B-6 20 mg, vitamin B-12 0.5 mg)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 24032554

Group type: EXPERIMENTAL
Intervention: ixekizumab 10, 25, 75 or 150 mg subcutaneously
Number of subjects: 114
Study: 21679091

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB)
Number of subjects: 0
Study: 19538811

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1000 mg Ca)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Calcium citrate (1000 mg Ca)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Potassium citrate (2250 mg K)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17091418

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Topical lidocaine treatment
Number of subjects: 46
Study: 15037402

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (80 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11894976

Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (0.45 g ethanol/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water ingestion
Number of subjects: 14
Study: 9592984

Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose, continuous intravenous infusion)
Number of subjects: 70
Study: 11654164

Group type: EXPERIMENTAL
Intervention: Persons with AIDS (PWAs)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Persons with homicidal intent
Number of subjects: 600
Study: 3203010

Group type: EXPERIMENTAL
Intervention: Monthly maintenance therapy consisting of thioguanine 100 mg/m2 twice daily and etoposide 100 mg/m2 twice daily (days 1-5) alternating with CCNU 50 mg/m2 once to a total of 6 courses.
Number of subjects: 64

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 64
Study: 30477620

Group type: EXPERIMENTAL
Intervention: RSV subtype A
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: RSV subtype B
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: NA1 genotype
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ON1 genotype
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nucleotide and amino acid homology
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Isolates of subtype A
Number of subjects: 200
Study: 28463149

Group type: EXPERIMENTAL
Intervention: Long-term ADT (LTAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month plus an additional 24 months of monthly goserelin)
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Long-term ADT (LTAD)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month)
Number of subjects: 1554
Study: 23771813

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program (intervention group)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Minimal intervention (control group)
Number of subjects: 292
Study: 23540577

Group type: EXPERIMENTAL
Intervention: Physical therapy program
Number of subjects: 452
Study: 21958949

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control targeting HbA(1c) to less than 6.0% (42 mmol/mol)
Number of subjects: 2977

Group type: COMPARATOR
Intervention: Standard glycaemic control targeting HbA(1c) to 7.0-7.9% (53-63 mmol/mol)
Number of subjects: 2977

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control
Number of subjects: 2977

Group type: COMPARATOR
Intervention: Standard glycaemic control
Number of subjects: 2977
Study: 18241743

Group type: EXPERIMENTAL
Intervention: TEVAR with Zenith TX2 Endovascular Graft
Number of subjects: 230

Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 230
Study: 16646115

Group type: EXPERIMENTAL
Intervention: Traumatic brain injury (TBI) group
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (matched for age, sex, and education), N=13
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: TBI group
Number of subjects: 11
Study: 12707558

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Inpatient psychiatric hospitalization
Number of subjects: 156
Study: 10897077

Group type: EXPERIMENTAL
Intervention: Perceptions of family relations and mothers' perceptions of daughters' weight at Time 1
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Previous body image and dieting behaviors
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Girls' body image
Number of subjects: 77
Study: 8797346

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (E7155) low dose (0.025 mmol/kg)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (E7155) medium dose (0.05 mmol/kg)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (E7155) high dose (0.1 mmol/kg)
Number of subjects: 79
Study: 1514709

Group type: EXPERIMENTAL
Intervention: Iomeprol, 150 mg iodine/mL
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iopamidol, 150 mg iodine/mL
Number of subjects: 100
Study: 6402934

Group type: EXPERIMENTAL
Intervention: CHAP regimen (doxorubicin and cisplatin plus hexamethylmelamine and cyclophosphamide)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Adriamycin-cisplatin (AP) regimen
Number of subjects: 100
Study: 31968102

Group type: EXPERIMENTAL
Intervention: Higher HDL-C levels (genetic predisposition)
Number of subjects: 617303

Group type: EXPERIMENTAL
Intervention: HDL-C raising genetic variants in the gene locus of CETP inhibitors
Number of subjects: 617303
Study: 31582195

Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Supportive Therapy for Cognitively Impaired
Number of subjects: 26
Study: 30002437

Group type: EXPERIMENTAL
Intervention: PF-05280014
Number of subjects: 226

Group type: COMPARATOR
Intervention: trastuzumab-EU
Number of subjects: 226
Study: 26963909

Group type: EXPERIMENTAL
Intervention: OEPA chemotherapy
Number of subjects: 100
Study: 24504431

Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI) for four times per week for 15 min at 15°C
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (passive recovery)
Number of subjects: 34
Study: 22540738

Group type: EXPERIMENTAL
Intervention: Enhanced handling and positioning experiences
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control experiences
Number of subjects: 28
Study: 20075695

Group type: EXPERIMENTAL
Intervention: Fiber supplementation for fecal incontinence (FI), specific dosage and duration not mentioned.
Number of subjects: 0
Study: 17327409

Group type: EXPERIMENTAL
Intervention: Eltrombopag (5, 10, 25, 30, 50, and 75 mg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 16263675

Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (North American Rescue Products, Inc.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Emergency & Military Tourniquet (Delfi Medical Innovations, Inc.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Special Operations Forces Tactical Tourniquet (Tactical Medical Solutions, LLC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fourth tourniquet tested in experiment I
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fourth tourniquet tested in experiment II
Number of subjects: 30
Study: 16968792

Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose PET scan in hyperthyroid patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose PET scan in hyperthyroid patients with increased anxiety
Number of subjects: 12
Study: 10642736

Group type: EXPERIMENTAL
Intervention: Localized short echo time magnetic resonance (MR) spectra analysis in active lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Localized short echo time magnetic resonance (MR) spectra analysis in chronic lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Localized short echo time magnetic resonance (MR) spectra analysis in normal‐appearing white matter
Number of subjects: 0
Study: 8672759

Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg daily for 3 weeks, 15 mg for 1 week, and no prednisolone for 2 weeks prior to lymphoblastoid IFN therapy (Group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily for 2 weeks, 30 mg for 2 weeks, 20 mg for 2 weeks, and no prednisolone for 2 weeks prior to INF alpha‐2a therapy (Group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher dose of prednisolone (40 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Non-cirrhotic patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with clinical rebound
Number of subjects: 100
Study: 1298321

Group type: EXPERIMENTAL
Intervention: Centrix System rubber points alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Centrix System rubber points plus Caulk's Prisma Gloss fine and super-fine pastes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caulk's Enhance disks plus Caulk's Prisma Gloss fine and super-fine pastes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3M Sof-flex disks alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enhance disks only without using the Prisma Gloss pastes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sof-flex disks plus Kerr's Lustre Paste
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sof-flex disks
Number of subjects: 30
Study: 6402387

Group type: EXPERIMENTAL
Intervention: 1.0 mg dl-norgestrel and 0.1 mg ethinylestradiol (EE) administered orally at 36 hours after LH peak and again at 48 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Endometrial biopsies from treatment cycle
Number of subjects: 12

Group type: COMPARATOR
Intervention: Endometrial biopsies from control cycle
Number of subjects: 12
Study: 31774400

Group type: EXPERIMENTAL
Intervention: MPathic-VR simulation
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study: 29076878

Group type: EXPERIMENTAL
Intervention: Housing voucher receipt (intervention)
Number of subjects: 0
Study: 26773183

Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy (QT) for 10 days
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Sequential therapy (ST) for 10 days
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (CT) for 10 days
Number of subjects: 390
Study: 24707778

Group type: EXPERIMENTAL
Intervention: Adaptive inhibitory control training
Number of subjects: 122

Group type: COMPARATOR
Intervention: Active control (nonadaptive version)
Number of subjects: 122
Study: 22189188

Group type: EXPERIMENTAL
Intervention: MCP joint blocking splint
Number of subjects: 30

Group type: COMPARATOR
Intervention: DIP joint blocking splint
Number of subjects: 30
Study: 20457580

Group type: EXPERIMENTAL
Intervention: Zygoma anchorage system (ZAS) with PG retraction springs
Number of subjects: 30

Group type: COMPARATOR
Intervention: PG retraction springs only
Number of subjects: 30
Study: 18614781

Group type: COMPARATOR
Intervention: Standard oxygen therapy (367 patients)
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (CPAP, 346 patients)
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIPPV, 356 patients)
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (CPAP)
Number of subjects: 1069
Study: 15642905

Group type: EXPERIMENTAL
Intervention: MRI scans before antiepileptic medication and follow-up MRI scans after 1, 2 to 3, and 5 years of treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Individual analysis of patients with HC damage
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Patients with HC damage
Number of subjects: 103
Study: 12145071

Group type: EXPERIMENTAL
Intervention: Forearm IVRA with 100 mg lidocaine and 10 mg ketorolac
Number of subjects: 100

Group type: COMPARATOR
Intervention: Upper Arm IVRA with 200 mg lidocaine and 20 mg ketorolac
Number of subjects: 100
Study: 10523683

Group type: EXPERIMENTAL
Intervention: High dThdPase activity in primary tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dThdPase activity in tumors with venous invasion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dThdPase activity in metastatic lymph nodes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intratumoral heterogeneity of dThdPase activity
Number of subjects: 0
Study: 7733838

Group type: EXPERIMENTAL
Intervention: Levorotatory form of hydroxytryptophan (1000 mg/d)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 31779988

Group type: EXPERIMENTAL
Intervention: Thermotherapy + TENS
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Thermotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 29382250

Group type: EXPERIMENTAL
Intervention: Individual Enabling and Support (IES)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 61
Study: 26585355

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 170

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 170
Study: 24402803

Group type: EXPERIMENTAL
Intervention: Advancement of catheters with a leading guidewire over the aortic arch
Number of subjects: 41

Group type: COMPARATOR
Intervention: Advancement of catheters without a guidewire over the aortic arch
Number of subjects: 41
Study: 22495787

Group type: EXPERIMENTAL
Intervention: UC781 vaginal gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19369187

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (n = 56)
Number of subjects: 107

Group type: COMPARATOR
Intervention: No additional treatment (Control group, n = 46)
Number of subjects: 107
Study: 17962710

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 15024596

Group type: EXPERIMENTAL
Intervention: Single Stapled Trans‐Anal Prolapsectomy with Perineal Levatorplasty (STAPL Group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Double Stapled Trans‐Anal Rectal Resection (STARR Group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: STARR Group
Number of subjects: 50

Group type: COMPARATOR
Intervention: STAPL Group
Number of subjects: 50
Study: 11597813

Group type: EXPERIMENTAL
Intervention: Accelerated Hyperfractionated (AH) whole‐brain radiation therapy (1.6 Gy b.i.d. to 54.4 Gy)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Accelerated Fractionation (AF) whole‐brain radiation therapy (3 Gy q.d. to 30 Gy)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Control of brain metastases (radiologically controlled)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Uncontrolled brain metastases
Number of subjects: 445
Study: 9688452

Group type: COMPARATOR
Intervention: Ceftazidime 3 g daily + amikacin (reference regimen)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam + amikacin
Number of subjects: 608
Study: 8082347

Group type: EXPERIMENTAL
Intervention: Bolus rt-PA (0.6 mg/kg/15 min, maximum of 50 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2-h rt-PA (100 mg over 2 h)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bolus rt-PA
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2-h rt-PA
Number of subjects: 90
Study: 2537125

Group type: EXPERIMENTAL
Intervention: Subcuticular non-absorbable suture for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcuticular polyglycolic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional interrupted sutures
Number of subjects: 0
Study: 1091965

Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid (ASA) preparation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Plain acetylsalicylic acid (ASA) tablets
Number of subjects: 18
Study: 31532029

Group type: EXPERIMENTAL
Intervention: subanesthetic S-Ketamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30159738

Group type: EXPERIMENTAL
Intervention: Monovisc™ (4 ml single injection)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Saline (4 ml injection of 0.9% saline)
Number of subjects: 369
Study: 28287802

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy® Plus group prenatal care
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Individual prenatal care
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Increased depressive symptoms from second to third trimester
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Third trimester depressive symptoms
Number of subjects: 1135
Study: 25269659

Group type: EXPERIMENTAL
Intervention: Pump 2 (Asante Snap Insulin Pump)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pump 1 (Medtronic Revel 723)
Number of subjects: 28
Study: 22834767

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21270359

Group type: EXPERIMENTAL
Intervention: 15 μg/d cholecalciferol (D3) supplementation
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: 5 μg/d cholecalciferol (D3)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: 10 μg/d cholecalciferol (D3)
Number of subjects: 413
Study: 19292217

Group type: EXPERIMENTAL
Intervention: S-ROM prosthesis
Number of subjects: 10
Study: 17137511

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous adenosine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12